This Med Tech Innovator Just Doubled, And It Can Do It Again

When we last talked last Friday, I showed you how a software executive founded biotech company Veeva Systems Inc. (VEEVand turned his expertise in cloud software into a 1,253% gain for investors.

That’s over the last seven years, mind you. Enough to turn $25,000 into $338,250 and up to $1.35 million in the next four years.

Here’s the thing. If you’re a “set-and-forget” investor happy to match the S&P 500, you’ve come to the wrong place.

We’re here to crush the market with the foremost innovative tech leaders.

Over the seven years I’m talking about, the S&P 500 gained a very respectable 128%.

Not bad. Unless you compare it to VEEV.

Veeva beat it by a staggering 879%.

Today, I’m following up to show you why Veeva is such a great company and is set to double again in about 21 months…

Who Is Peter Gassner?

Last time we spoke, I told you about Peter Gassner, Veeva’s founder. As you may recall, his background is in software, not biotech.

He spent years at International Business Machines Corp. (IBM) and other software firms, before eventually becoming senior vice president at (CRM).

Gassner was a powerful force behind Salesforce’s very successful IPO in 2004 was the first time most investors had ever heard of cloud-based software.

Just three years later, Gassner took that cloud expertise and decided to found Veeva and bring the cloud to biotech.

It became a transformational moment for the $1.2 trillion drug sector by simplifying some of its toughest tasks beyond drug discovery. And the cloud allowed for fast and convenient collaboration

The Biotech Challenge

See, despite the huge potential and importance of biotech, the drug industry is still filled with time-consuming and expensive headaches.

It costs a small fortune for a company to build software to track the testing, sales, and all of the regulatory data they must have on hand. Especially as all this data has to have state-of-the-art security to comply with strict patient privacy laws.

1 2 3
View single page >> |

Disclosure: None.

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.